U.S. Patent 10,426,839: Meloxicam, Bicarbonate, Bioavailability and Generic Entry Analysis

U.S. Patent No. 10,426,839 protects a narrow method of administering meloxicam in a solid dosage form containing 400 to 900 mg of bicarbonate and achieving specified human pharmacokinetic results. Its commercial value depends on whether a competing product uses bicarbonate within the claimed range and produces the required median Cmax and bioavailability improvement. The patent does not broadly claim every meloxicam tablet, every fast-acting meloxicam formulation, or meloxicam itself.

The strongest commercial embodiment is a tablet containing approximately 15 mg meloxicam and 500 mg sodium bicarbonate. Dependent claims add sulfobutyl ether beta-cyclodextrin, esomeprazole, defined bioavailability improvements, and treatment of inflammatory and arthritic pain.

What does U.S. Patent 10,426,839 protect?

The patent protects a human-treatment method requiring all of the following elements:

Required limitation	Scope
Active ingredient	Meloxicam
Dosage form	Solid dosage form administered orally
Bicarbonate	400 mg to 900 mg
Comparator	A meloxicam dosage form without bicarbonate and without carbonate, or a pH-matched potassium-carbonate comparator
Pharmacokinetic result	Median meloxicam Cmax of approximately 1,800 to 3,000 ng/mL in fasted human subjects
Claimed effect	Improved oral bioavailability
Patient	Human being

Claim 1 is an outcome-limited method claim. A product is not within the literal scope merely because it contains meloxicam and bicarbonate. The accused administration must also satisfy the claimed human pharmacokinetic and comparative bioavailability limitations.

The principal protected concept is the use of bicarbonate to improve meloxicam exposure without relying solely on a comparable pH increase produced by potassium carbonate. That distinction narrows the claim but gives it technical specificity.

How do the independent and dependent claims differ?

Claim 1: Core bicarbonate and pharmacokinetic claim

Claim 1 requires:

Oral administration to a human.
A solid dosage form.
Meloxicam and bicarbonate in the same dosage form.
400 to 900 mg of bicarbonate.
Improved bioavailability compared with one of two specified reference formulations.
Median Cmax of approximately 1,800 to 3,000 ng/mL in fasted human subjects.

The claim covers sodium bicarbonate and potassium bicarbonate because those alternatives are expressly recited in claim 9. It does not expressly cover every bicarbonate salt or every dosage form outside the claimed quantity range.

The reference-formulation limitation is important. The claim compares the claimed dosage form with either:

a formulation containing the same amount of meloxicam but no bicarbonate and no carbonate; or
a formulation containing the same amount of meloxicam and enough potassium carbonate to achieve approximately the same pH.

This language attempts to distinguish a bicarbonate effect from a generic alkalinization or pH effect.

Claims 2 and 3: Cyclodextrin embodiments

Claim 2 adds a cyclodextrin. Claim 3 narrows that limitation to sulfobutyl ether beta-cyclodextrin, commonly abbreviated SBEβCD.

These claims create a separate formulation profile involving:

meloxicam;
bicarbonate;
cyclodextrin; and
the same core pharmacokinetic requirements inherited from claim 1.

SBEβCD can affect solubilization and dissolution behavior. A competing product without a cyclodextrin may avoid claims 2 and 3 while remaining potentially relevant to claim 1.

Claims 4 and 5: Esomeprazole combinations

Claim 4 adds an acid inhibitor. Claim 5 specifies esomeprazole. Claim 12 narrows the amount of esomeprazole to approximately 30 to 50 mg.

The resulting combination is technically and commercially narrower:

1 to 50 mg meloxicam, if claim 7 is also met;
approximately 15 mg meloxicam under claim 8;
400 to 900 mg bicarbonate;
SBEβCD if claims 2 and 3 are met; and
approximately 30 to 50 mg esomeprazole under claim 12.

A meloxicam product containing bicarbonate but no esomeprazole would not literally meet claims 4, 5 or 12, although claim 1 could remain relevant.

Claims 6 to 12: Dosage-form and composition narrowing

Claim	Limitation
6	Tablet
7	1 to 50 mg meloxicam
8	Approximately 15 mg meloxicam
9	Sodium bicarbonate or potassium bicarbonate
10	400 to 600 mg sodium bicarbonate
11	Approximately 500 mg sodium bicarbonate
12	Approximately 30 to 50 mg esomeprazole

Claims 8 and 11 identify the most commercially practical embodiment: a 15 mg meloxicam tablet containing approximately 500 mg sodium bicarbonate.

Claims 13 to 17: Bioavailability improvement thresholds

These claims define increasing bioavailability results:

claim 13: at least approximately 10%;
claim 14: at least approximately 30% with cyclodextrin;
claim 15: at least approximately 50%;
claim 16: approximately 100%; and
claim 17: approximately 200% with cyclodextrin.

The percentages appear to be relative to the reference dosage forms specified in claim 1. They do not necessarily mean absolute bioavailability percentages. They more likely describe a relative increase in exposure, such as area under the concentration-time curve.

Claims 18 and 19: Narrower Cmax ranges

Claim 18 narrows median Cmax to approximately 2,000 to 2,500 ng/mL.

Claim 19 narrows it further to approximately 2,200 to 2,400 ng/mL.

These claims may be easier to practice with a formulation designed around a specific clinical pharmacokinetic profile, but they also create evidentiary issues. An infringement analysis would need to establish the relevant study population, fasting conditions, meloxicam dose, analytical method, and statistical treatment.

Claims 20 to 22: Therapeutic use

Claims 20 through 22 limit the method to treatment of:

pain;
inflammatory pain;
osteoarthritis;
rheumatoid arthritis; or
juvenile rheumatoid arthritis.

These claims are method-of-use claims rather than composition claims. They are more relevant to induced-infringement theories involving labeling, promotional materials, prescribing instructions, or demonstrated use in the claimed conditions.

What formulation is the patent’s commercial center of gravity?

The highest-value claim cluster is:

Attribute	Narrow commercial embodiment
Meloxicam	Approximately 15 mg
Bicarbonate	Approximately 500 mg sodium bicarbonate
Dosage form	Tablet
Optional solubilizer	SBEβCD
Optional acid inhibitor	30 to 50 mg esomeprazole
Pharmacokinetics	Median Cmax approximately 2,200 to 2,400 ng/mL
Bioavailability	At least approximately 50%, 100% or 200%, depending on the claim
Use	Pain or arthritis treatment

The patent is therefore strongest against a product intentionally engineered around the disclosed bicarbonate-enhanced meloxicam platform. It is materially weaker against:

a conventional meloxicam tablet without bicarbonate;
a submicron or nanocrystal meloxicam product without bicarbonate;
an oral liquid;
a product containing less than 400 mg or more than 900 mg bicarbonate;
a product using a non-bicarbonate alkalizer; or
a product that does not produce the claimed fasted-human Cmax.

How broad is the patent compared with ordinary meloxicam products?

The patent does not cover ordinary meloxicam products as a class.

The FDA-approved Mobic label describes meloxicam tablets and oral suspension for osteoarthritis and rheumatoid arthritis. Conventional products generally rely on the intrinsic formulation and do not necessarily contain the bicarbonate quantities specified in U.S. Patent 10,426,839 (FDA, Mobic Prescribing Information).

Product or technology category	Likely relevance to Patent 10,426,839
Conventional meloxicam tablet	Low unless it contains the claimed bicarbonate and meets the PK limitations
Meloxicam oral suspension	Generally outside the solid-dosage-form limitation
Meloxicam capsule	Potentially relevant only if it contains the required bicarbonate and meets the other limitations
Orally disintegrating meloxicam tablet	Potentially relevant, but dosage-form format alone is insufficient
Submicron or nanocrystal meloxicam	Potentially differentiated if no bicarbonate is used
Meloxicam plus esomeprazole	Relevant to claims 4, 5 and 12 if bicarbonate and PK limitations are also met
Meloxicam plus cyclodextrin	Relevant to claims 2, 3, 14 and 17 if bicarbonate and PK limitations are also met
Injectable meloxicam	Outside the oral solid-dosage-form limitation
Topical meloxicam	Outside the claimed oral administration method

This claim structure leaves room for design-around strategies based on particle engineering, amorphous solid dispersions, alternative solubilizers, different alkalizers, liquid formulations, or bicarbonate quantities outside the claimed range.

What is the patent’s technical point?

Meloxicam is a poorly water-soluble, weakly acidic NSAID. Formulation strategies can attempt to increase dissolution, accelerate absorption, or raise systemic exposure.

The patent distinguishes bicarbonate from potassium carbonate even when the two systems produce approximately the same pH. That limitation suggests that the claimed benefit is not characterized solely as an acid-neutralization effect. The patent instead frames bicarbonate as producing a superior oral-bioavailability result under the specified formulation and clinical conditions.

The Cmax limitation gives the patent a measurable pharmacokinetic anchor. It also creates litigation risk because the claim uses terms such as:

“about”;
“improved”;
“has been shown to have”;
“median Cmax”; and
“fasted human subjects.”

Those terms may require fact-specific construction. A court could need to determine the acceptable range around each “about” value, the comparator used to measure improvement, and whether the claimed Cmax is a formulation property or a required result of the accused administration.

How strong is the patent estate?

Strengths

The patent has several features that can support validity and enforcement:

It claims a specific active ingredient and excipient combination.
It uses a defined bicarbonate quantity.
It recites comparative testing against both a non-carbonate formulation and a pH-matched carbonate formulation.
It includes human fasted-subject pharmacokinetic data.
It contains narrower claims directed to sodium bicarbonate, 15 mg meloxicam and approximately 500 mg bicarbonate.
It includes formulation and therapeutic-use fallback positions.

Vulnerabilities

The main vulnerabilities are claim construction, enablement and prior art.

Potential validity issues include:

prior disclosures of meloxicam with bicarbonate or other alkalizing agents;
obviousness based on combining known meloxicam formulations with bicarbonate;
whether the full 400 to 900 mg range is enabled;
whether the stated Cmax range is reproducible across patients and manufacturing lots;
whether “improved bioavailability” is sufficiently definite;
whether the potassium-carbonate comparator is adequately defined;
whether the claims require a particular clinical study design; and
whether the specification supports all combinations of bicarbonate, cyclodextrin, esomeprazole and meloxicam dose.

The narrower claims may provide useful fallback positions, but each added limitation also reduces the number of potentially infringing products.

When does U.S. Patent 10,426,839 lose exclusivity?

The patent’s exact expiration date cannot be established from the claims alone. U.S. utility patents generally expire 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any available patent-term extension under 35 U.S.C. §§ 154 and 156 (U.S. Patent and Trademark Office, n.d.; 35 U.S.C. §§ 154, 156).

The issue date does not by itself determine the expiration date. The controlling analysis requires the patent’s:

earliest effective priority date;
nonprovisional filing history;
patent-term adjustment;
terminal disclaimer status; and
any regulatory patent-term extension.

The patent’s expiration date should therefore be taken from the current USPTO Patent Center record and the applicable Orange Book entry, if the patent is listed for an FDA-approved product.

What is the Orange Book status of the patent?

Patent 10,426,839 is relevant to Orange Book analysis only if it is listed by the applicable new-drug application holder for an approved product. A patent is not automatically Orange Book-listed because it covers a pharmaceutical formulation or method.

The FDA Orange Book distinguishes among:

drug-substance patents;
drug-product patents;
method-of-use patents; and
patents that are not eligible for listing.

The claims supplied are primarily method-of-use claims, although they depend heavily on formulation characteristics. Any listing would need to satisfy FDA patent-submission rules and the statutory listing requirements under the Hatch-Waxman framework (FDA, Orange Book; 21 C.F.R. § 314.53).

The practical questions are whether:

the patent is listed against a specific meloxicam NDA;
the listed claims correspond to the approved labeling;
the approved product contains the claimed bicarbonate;
a use code covers pain or arthritis treatment; and
the listing remains active.

What Paragraph IV risks exist for meloxicam products?

A generic applicant could challenge an Orange Book-listed patent through an ANDA Paragraph IV certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV). The likely positions would differ by product design.

ANDA strategy	Potential Paragraph IV position
Conventional meloxicam without bicarbonate	Noninfringement based on absence of bicarbonate
Bicarbonate below 400 mg	Noninfringement based on quantity
Bicarbonate above 900 mg	Noninfringement based on quantity
Alternative alkalizer	Noninfringement based on absence of bicarbonate
No demonstrated fasted Cmax in claimed range	Noninfringement or invalidity position based on result limitation
No arthritis indication in labeling	Potential defense to claims 20 to 22
Meloxicam plus bicarbonate with matching PK	Higher infringement exposure
Meloxicam plus bicarbonate and SBEβCD	Highest exposure to claims 1 to 3, 14 and 17

Because claim 1 is a method claim, infringement may depend on the product label and actual use. A generic label that instructs treatment of osteoarthritis or rheumatoid arthritis could create greater exposure to claims 20 through 22 than a label with a narrower indication.

A Paragraph IV notice would not establish infringement. It would trigger the statutory litigation and stay framework if the patent were properly listed and the NDA holder sued within the statutory period.

Which companies are challenging the patent?

No challenger, ANDA filer, litigation docket, or settlement agreement can be reliably attributed to U.S. Patent 10,426,839 from the claim text alone. Patent litigation and Paragraph IV activity must be confirmed through PACER, district-court docket records, USPTO Patent Center, FDA Orange Book data and FDA litigation correspondence.

A patent-family record also does not establish that a company has filed an ANDA or challenged validity. Assignment records show ownership or security interests, not commercial enforcement activity.

Does the patent create biosimilar risk?

No. Meloxicam is a chemically synthesized small-molecule drug. The relevant competitive pathway is an ANDA under Hatch-Waxman, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The absence of biosimilar exposure does not eliminate competition risk. Generic meloxicam manufacturers can enter through:

a formulation that avoids bicarbonate;
a different dosage form;
an alternative delivery technology;
a Paragraph IV challenge;
a 505(b)(2) application; or
an authorized-generic or licensing arrangement.

What manufacturing and IP barriers matter?

The patent’s manufacturing relevance is indirect. It does not, based on the supplied claims, claim a manufacturing process, granulation sequence, particle-size distribution, compression force, coating method or release profile.

Commercial barriers may still arise from:

achieving uniform distribution of 400 to 900 mg bicarbonate;
maintaining tablet size and swallowability;
preventing moisture-related stability problems;
controlling dissolution and disintegration;
reproducing the claimed Cmax across subjects;
combining bicarbonate with SBEβCD;
combining the formulation with 30 to 50 mg esomeprazole; and
demonstrating bioequivalence for an ANDA or clinical benefit for a 505(b)(2) application.

A competitor may avoid this patent but encounter separate patents covering particle size, solid-state form, excipient architecture, dosage-form design, manufacturing processes or approved uses. A freedom-to-operate review must therefore examine the entire meloxicam patent family and product-specific patents, not only U.S. Patent 10,426,839.

How does this patent compare with conventional meloxicam exclusivity?

Issue	Conventional meloxicam product	Patent 10,426,839 formulation
Protection type	Active ingredient, formulation or use patents may apply	Narrow method claims
Bicarbonate required	No	Yes, 400 to 900 mg
Human PK result required	Usually not in a basic composition claim	Yes
Cmax limitation	Usually absent	Approximately 1,800 to 3,000 ng/mL
Cyclodextrin	Not required	Required for claims 2, 3, 14 and 17
Esomeprazole	Not required	Required for claims 4, 5 and 12
Generic design-around	Broad formulation flexibility	Relatively substantial
Biosimilar pathway	Not applicable	Not applicable
Main litigation issue	Composition, use or formulation scope	Whether all PK and administration limitations are met

Key Takeaways

U.S. Patent 10,426,839 is a narrow, outcome-limited method patent for improving meloxicam oral bioavailability with 400 to 900 mg bicarbonate.
The strongest disclosed commercial embodiment is approximately 15 mg meloxicam with 500 mg sodium bicarbonate in a tablet.
Claims 2 and 3 add cyclodextrin, with claim 3 limited to SBEβCD.
Claims 4, 5 and 12 cover formulations using esomeprazole, including approximately 30 to 50 mg.
The patent requires a specified fasted-human median Cmax, making clinical pharmacokinetic evidence central to infringement.
Conventional meloxicam tablets without bicarbonate are not automatically within the patent’s scope.
Generic risk is concentrated in products that deliberately reproduce the bicarbonate formulation and PK profile.
The patent is not relevant to biosimilar competition because meloxicam is a small molecule.
Exact expiration, Orange Book listing, ownership, litigation and settlement status require current USPTO, FDA and court-record verification.
The patent does not, on the supplied claims, create a manufacturing-process monopoly.

FAQs

Can a meloxicam product infringe if it contains sodium bicarbonate but less than 400 mg?

A product containing less than 400 mg sodium bicarbonate would generally fall outside the literal range in claim 1 and the related dependent claims, subject to claim construction and any doctrine-of-equivalents analysis.

Does a 15 mg meloxicam dose alone fall within the patent?

No. The 15 mg limitation in claim 8 is only one element. The product must also contain the required bicarbonate, satisfy the solid oral dosage-form requirement, meet the comparator-based bioavailability limitation and produce the claimed Cmax result.

Does the patent cover potassium carbonate formulations?

Not generally. Claim 1 uses a potassium-carbonate formulation as a comparator. That language does not make potassium carbonate an alternative claimed active excipient. Claims 9 through 11 identify sodium bicarbonate and potassium bicarbonate instead.

Can a liquid meloxicam formulation avoid the patent?

A liquid formulation has a strong noninfringement position against the solid-dosage-form limitation in claim 1. Other patents or regulatory requirements may still apply.

Is esomeprazole required for the main invention?

No. Esomeprazole is required only for claims 4, 5 and 12. The independent claim covers a meloxicam-bicarbonate solid dosage form without requiring esomeprazole.

References

U.S. Patent No. 10,426,839, “Methods of improving oral bioavailability of meloxicam,” claims 1–22 (2019).
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension. https://www.uspto.gov
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov
U.S. Food and Drug Administration. (n.d.). Mobic (meloxicam) prescribing information. https://www.accessdata.fda.gov
21 C.F.R. § 314.53. Patent information submitted by applicants who submit an NDA.
35 U.S.C. §§ 154, 156. Patent term and patent term extension.
21 U.S.C. § 355(j). Abbreviated applications for new drugs.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes	10,426,839	⤷ Start Trial				IMPROVING ORAL BIOAVAILABILITY OF MELOXICAM	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016218992	⤷ Start Trial
Australia	2018205790	⤷ Start Trial
Australia	2018265411	⤷ Start Trial
Australia	2019203328	⤷ Start Trial
Australia	2019297360	⤷ Start Trial
Australia	2020205306	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,426,839

Which drugs does patent 10,426,839 protect, and when does it expire?

Summary for Patent: 10,426,839